Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04047797 · ClinicalTrials.gov registry record · Phase 2
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT04047797: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT04047797 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04047797, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with rituximab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving ixazomib and rituximab may work better in treating patients with mantle cell lymphoma compared to rituximab alone.
Interventions
- BIOLOGICAL Rituximab
- DRUG Ixazomib Citrate
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-28 |
| Est. Completion | 2025-04-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04047797
The ClinicalTrials.gov registry entry for NCT04047797 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT04047797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04047797 about?
NCT04047797 is a clinical study titled "Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma". This phase II trial studies how well ixazomib and rituximab work in treating patients with mantle cell lymphoma that has come back (relapsed) or does not respond (refractory) to BTK inhibitor treatment. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell grow...
What is the current status of trial NCT04047797?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-08-28. Estimated completion is 2025-04-11.
What interventions are being tested in trial NCT04047797?
The interventions under investigation include: Rituximab (BIOLOGICAL), Ixazomib Citrate (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT04047797?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.